These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27938964)

  • 1. Preservative content in generic and brand name glaucoma eye drops.
    Hallaji NA; Rao PP; Trope GE
    Can J Ophthalmol; 2016 Dec; 51(6):492. PubMed ID: 27938964
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry.
    Kahook MY; Fechtner RD; Katz LJ; Noecker RJ; Ammar DA
    Curr Eye Res; 2012 Feb; 37(2):101-8. PubMed ID: 22040280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generic versus brand-name North American topical glaucoma drops.
    Mammo ZN; Flanagan JG; James DF; Trope GE
    Can J Ophthalmol; 2012 Feb; 47(1):55-61. PubMed ID: 22333853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of phosphate concentration in glaucoma eye drops commercially available in Spain.
    Martínez-Soroa I; de Frutos-Lezaun M; Ostra Beldarrain M; Egía Zurutuza A; Irastorza Larburu MB; Bachiller Cacho MP
    Arch Soc Esp Oftalmol; 2016 Aug; 91(8):363-71. PubMed ID: 27017538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using of thin-layer chromatography for identification and quantitative determination of benzalkonium chloride in eye drops.
    Chyła A; Zelazowska E
    Acta Pol Pharm; 1999; 56(6):419-23. PubMed ID: 10715887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The physical properties of generic latanoprost ophthalmic solutions are not identical.
    Kolko M; Koch Jensen P
    Acta Ophthalmol; 2017 Jun; 95(4):370-373. PubMed ID: 28229536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbial contamination of eye drops.
    Taşli H; Coşar G
    Cent Eur J Public Health; 2001 Aug; 9(3):162-4. PubMed ID: 11505742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antiglaucoma drugs--content of preservatives and the patient's compliance].
    Výborný P; Sejcková L
    Cesk Slov Oftalmol; 2006 Jul; 62(4):270-2, 274. PubMed ID: 16895060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of latanoprost in generic formulations using controlled degradation and patient usage simulation studies.
    Velpandian T; Kotnala A; Halder N; Ravi AK; Archunan V; Sihota R
    Curr Eye Res; 2015 May; 40(6):561-71. PubMed ID: 25494824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi Arabia.
    Al-Jumaian N; Malik R; Khandekar R; Al-Humaidan A; Al-Madany R; Al-Qahtani R; Altowairqi A; Al-Theeb A; Zaman B; Al-Djasim L; Craven ER; Edward DP
    Middle East Afr J Ophthalmol; 2016; 23(4):296-301. PubMed ID: 27994392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of surfactants suitable for stabilizing of latanoprost.
    Ochiai A; Ohkuma M; Danjo K
    Int J Pharm; 2012 Oct; 436(1-2):732-7. PubMed ID: 22842310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
    Ammar DA; Noecker RJ; Kahook MY
    Adv Ther; 2010 Nov; 27(11):837-45. PubMed ID: 20931366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localisation and quantification of benzalkonium chloride in eye tissue by TOF-SIMS imaging and liquid chromatography mass spectrometry.
    Desbenoit N; Schmitz-Afonso I; Baudouin C; Laprévote O; Touboul D; Brignole-Baudouin F; Brunelle A
    Anal Bioanal Chem; 2013 May; 405(12):4039-49. PubMed ID: 23430186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing Side Effects on Ocular Surface Caused by Glaucoma Eye Drops.
    Ferreras A; Figus M; Fogagnolo P; Iester M; Frezzotti P
    Curr Med Chem; 2019; 26(22):4223-4224. PubMed ID: 31612807
    [No Abstract]   [Full Text] [Related]  

  • 16. [Benzalkonium chloride daily dose--an important criterion in glaucoma treatment].
    Výborný P; Sicáková S
    Cesk Slov Oftalmol; 2011 Apr; 67(2):63-6. PubMed ID: 21751744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops.
    Kahook MY; Noecker R
    Adv Ther; 2008 Aug; 25(8):743-51. PubMed ID: 18670744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The stabilization mechanism of latanoprost.
    Ochiai A; Danjo K
    Int J Pharm; 2011 May; 410(1-2):23-30. PubMed ID: 21397673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.
    Kahook MY; Noecker RJ
    Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Original preparations versus generics--latanoprost: how similar is different?].
    Leitritz MA; Lipp HP; Voykov B; Ziemssen F
    Ophthalmologe; 2015 Feb; 112(2):127-39. PubMed ID: 25536956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.